How to defeat dementia

Comment

Elie Dolgin. Nature. 2016.

. 2016 Nov 10;539(7628):156-158.

doi: 10.1038/539156a.

No abstract available

Comment on

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group. Doody RS, et al. N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889. N Engl J Med. 2014. PMID: 24450890 Clinical Trial.
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. Sevigny J, et al. Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323. Nature. 2016. Update in: Nature. 2017 Jun 21;546(7659):564. doi: 10.1038/nature22809. PMID: 27582220 Updated.